Actively Recruiting
Rare Embryonal Tumors of the Central Nervous System: International Registry
Led by Immune Oncology Research Institute · Updated on 2025-05-08
300
Participants Needed
11
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Central nervous system (CNS) tumors are the most common solid malignancies among children. Although some types of CNS tumors like medulloblastomas and low-grade gliomas are widespread and well-studied, there is a huge number of rare diseases that need further research. This international registry aims to establish a large multicenter database of pediatric and young adult patients with rare embryonal tumors of the central nervous system and describe the clinical presentations, diagnostics, treatment regimens, and outcomes. Embryonal tumors with multilayered rosettes (ETMR), FOXR2-activated CNS neuroblastoma, cribriform neuroepithelial tumor, and CNS tumor with BCOR internal tandem duplication are extremely rare embryonal tumors some of which were first described in the last edition of the World Health Organization (WHO) Classification of Tumors of the Central Nervous System. Objectives of the registry are 1) to evaluate prognostic factors, 2) to identify diagnostic and treatment gaps, 3) to investigate the characteristics and outcome of the disease with different treatment regimens, and 4) to generate data-based prospective diagnostic and treatment recommendations.
CONDITIONS
Official Title
Rare Embryonal Tumors of the Central Nervous System: International Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with rare embryonal tumors of the CNS since 01.01.2010, including ETMR (ETANTR, ependymoblastoma, medulloepithelioma), FOXR2-activated CNS neuroblastoma, cribriform neuroepithelial tumor, CNS tumor with BCOR internal tandem duplication, and patients diagnosed with neuroblastoma or ganglioneuroblastoma without molecular genetic tests
- Patients aged 25 years or younger
- Signed informed consent for prospective patients aged 18 years or older
- Signed parental permission and child assent forms for prospective patients younger than 18 years
You will not qualify if you...
- CNS metastases of extracranial embryonal tumors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Hematology Center named after prof. R. Yeolyan
Yerevan, Armenia, 0014
Actively Recruiting
2
Children's Hospital of Eastern Ontario (CHEO)
Ottawa, Canada, K1H 8L1
Actively Recruiting
3
Semmelweis University
Budapest, Hungary, 1085
Actively Recruiting
4
National Cancer Institute, All India Institutes of Medical Sciences
New Delhi, India, 110029
Actively Recruiting
5
Oncology Department of Golestan hospital
Tehran, Iran, 16686 19551
Actively Recruiting
6
IRCCS Istituto Ospedale Pediatrico Bambino Gesù
Rome, Italy, 00163
Actively Recruiting
7
Hospital Civil de Guadalajara "Dr. Juan I. Menchaca"
Guadalajara, Mexico, 44340
Actively Recruiting
8
Centro Médico ABC
Mexico City, Mexico, 01120
Actively Recruiting
9
Hospital Nacional Alberto Sabogal Sologuren - EsSalud
Bellavista, Peru, 07011
Actively Recruiting
10
Hospital Nacional Edgardo Rebagliati Martins
Lima, Peru, 15072
Actively Recruiting
11
China Medical University Children's Hospital
Taichung, Taiwan, 40447
Actively Recruiting
Research Team
J
Julieta Hoveyan, MD
CONTACT
R
Ruzanna Papyan, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here